Pharmacogenomics (PGx) APOE Test
A targeted pharmacogenomic test evaluating APOE status to guide appropriate prescription of lecanemab-irmb and donanemab-azbt, powered by the Helix Exome+® platform.
Turnaround
6-9 days
Requery (SOQO)
≤ 5 minutes
Genes Tested
1
Panel Description
Lecanemab-irmb and donanemab-azbt are prescribed for patients with mild cognitive impairment (MCI) or mild dementia stage of Alzheimer's disease (AD) in order to slow the progression of MCI due to AD and mild AD dementia. APOE ε4 homozygotes have an increased risk for adverse events.
Order This Test
Contact our clinical team to order this panel or learn more.
Indications for Testing
Patients for whom lecanemab-irmb or donanemab-azbt treatments are being considered.
Methodology
This test utilizes next-generation sequencing to determine APOE status.
Technical Specifications
Reportable range
APOE: rs429358 and rs7412 (e2, e3, e4)
Technical note
E2/E4 and E1/E3 genotypes cannot be distinguished by this assay and are reported as E2/E4. E1 genotypes are reported as Indeterminate.
Genes Tested
1 genes included in this panel
Ordering Information
Turnaround Time
Typically 6-9 days (standard), Typically ≤ 5 minutes (requery)
Preferred Specimen
BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit
Shipping Instructions
Specimens to arrive at Helix within 96 hours of collection at ambient temperature.
Clinical Description
Lecanemab-irmb and donanemab-azbt are prescribed for patients with mild cognitive impairment (MCI) or mild dementia stage of Alzheimer's disease (AD) in order to slow the progression of MCI due to AD and mild AD dementia. APOE ε4 homozygotes have an increased risk for adverse events.
This test evaluates a patient’s APOE status, which can aid in appropriate prescription of lecanemab-irmb and donanemab-azbt.
Ready to order this test?
Contact our clinical team to order the Pharmacogenomics (PGx) APOE Test for your patients.